Discover 1,461 paid clinical trials in Tacoma, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,461
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
for
Dravet Syndrome
Location: Seattle WA, Rochester MN, Memphis TN, Ann Arbor MI,
Sponsor: Ionis Pharmaceuticals, Inc.
Sex: All
Age: 2 - 12
Code: NCT07531745
Phase 1, Phase 2, Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
for
Autoimmune Haemolytic Anaemia
Location: Seattle WA, Stanford CA, Duarte CA, Los Angeles CA,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07086976
Phase 3, Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
for
Chronic Graft Versus Host Disease
Location: Seattle WA, Vancouver, Los Angeles CA, Houston TX,
Sponsor: Sanofi
Sex: All
Age: 1 - 18
Code: NCT07116031
Phase 2, Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
for
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer,
Location: Seattle WA, San Francisco CA, Los Angeles CA, Aurora CO,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07066657
Phase 1, Recruiting
Venetoclax and Lintuzumab-Ac225 in AML Patients
for
Acute Myeloid Leukemia, Relapsed Adult AML
Location: Seattle WA, Los Angeles CA, Louisville KY,
Sponsor: Actinium Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03867682
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
for
NSCLC
Location: Seattle WA, Portland OR, Stanford CA, Los Angeles CA,
Sponsor: Ellipses Pharma
Sex: All
Age: 18+
Code: NCT05443126
Phase 1, Phase 2, Recruiting
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies